Repligen Corporation Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Repligen Corporation's estimated annual revenue is currently $50.2M per year.
- Repligen Corporation received $138.0M in venture funding in June 2017.
- Repligen Corporation's estimated revenue per employee is $155,000
- Repligen Corporation's total funding is $242.6M.
- Repligen Corporation has 324 Employees.
- Repligen Corporation grew their employee count by 22% last year.
- Repligen Corporation currently has 4 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$75.6M||488||N/A||N/A|
What Is Repligen Corporation?
Repligen is a bioprocessing-focused life sciences company bringing over 35 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies. Our manufacturing facilities are located at our Waltham, Massachusetts headquarters in the USA, and in Lund, Sweden, Weingarten, Germany , Rancho Dominguez, CA and Shrewsbury, MA. We market our products globally through a direct commercial organization in the U.S., Europe and Asia, as well as through strategic partners in select markets.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Michael LaBreck||Sales Director, Tangenx Products|
|Jon Snodgres||Chief Financial Officer|
|Tony Hunt||Chief Executive Officer|
|John McSweeney||Senior Director Of Financial Planning And Analysis||Email Available|
|Scott Pearce||Manager of FP&A|
|Alan Dion||Vice President Finance||Email Available|
|Gautam Choudhary||Vice President And General Manager-bioprocess Systems||Email Available|
|Joe Reale||Director Of Engineering||Email Available|
|Luis Costa||Quality Manager|
|Linda Federico||Director Customer Service||Email Available|
Repligen Corporation News
Based on Repligen Corporation's (NASDAQ:RGEN) earnings update in June 2019, analyst forecasts seem fairly subdued, as a 8.4% rise in ...
On Thursday, shares of Repligen Corporation (NASDAQ:RGEN) marked $94.23 per share versus a previous $90.85 closing price. With having ...
In its most recent trading session, Repligen Corporation (RGEN) dropped by -1.3% – here is what that looked like (as of 2019-09-09): ...
Repligen Corporation Funding
|2017-06-29||$138.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
Repligen Corporation Executive Hires
|2011-08-12||Robert A. Spurr||VP Sales/Marketing/Chief Commercial Of||Article|
|2012-09-24||Jonathan I Lieber||CFO||Article|
|2014-07-16||Jon Snodgres||Chief Financial Officer||Article|
|2016-10-19||Ralf Kuriyel||SVP Research & Development||Article|
Repligen Corporation Acquisitions
|2017-08-24||Spectrum Communications & Consulting, Inc.||Article|